Welcome to our dedicated page for Olema Pharmaceuticals news (Ticker: OLMA), a resource for investors and traders seeking the latest updates and insights on Olema Pharmaceuticals stock.
Olema Pharmaceuticals, Inc. reports clinical, corporate, and financing developments as a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer and other cancers. Olema Oncology updates commonly center on palazestrant (OP-1250), an orally available complete estrogen receptor antagonist and selective estrogen receptor degrader, and OP-3136, an orally available KAT6 inhibitor.
Recurring company news covers clinical and preclinical presentations at oncology meetings, endocrine-driven cancer biology, ER+/HER2- breast cancer studies, combination approaches with endocrine therapy and CDK inhibitors, operating results, public offerings, inducement equity grants, and board or management changes.
Olema Pharmaceuticals, Inc. has announced the pricing of its initial public offering of 11,000,000 shares at $19.00 per share, aiming to raise approximately $209.0 million before expenses. All shares are being offered by Olema, which has also given underwriters a 30-day option for an additional 1,650,000 shares. The shares are set to trade on the Nasdaq under the ticker symbol OLMA, starting November 19, 2020, with the offering expected to close on November 23, 2020. J.P. Morgan, Jefferies, and Cowen are leading the offering.